As the Official Cancer Center of the State of New Mexico and as a National Cancer Institute-Designated Cancer Center (2P30CA118100-08), it is our mission and goal to improve the quality of cancer care in our region, to develop outreach programs throughout our State that lay a foundation for community-based participatory research, and, to increase awareness, access, and participation of all New Mexicans in NCI-sponsored cancer screening, prevention, and therapeutic trials. With the highest proportion of Hispanics and American Indians of any State (41% non-Hispanic White, 46% Hispanic, and 10% American Indian), many of New Mexico's almost 2.0 million people experience unusual cancer patterns and tremendous cancer health disparities. The State of New Mexico is ranked 43rd in the United States for per capita income. According to the 2011 Census Bureau 18.4% of New Mexicans live below the poverty level versus the national average of 13%. Over 50% of New Mexicans live in rural areas of the State with often limited access to healthcare and 22.9% of New Mexicans were uninsured in 2009, according to the New Mexico Department of Health with a range of 4.8% to 31.6% among the counties in our State. The UNM Cancer Center's Office of Community Partnerships and Health Disparities works with our New Mexico MBCCOP program to facilitate community partnerships and education programs in conjunction with community partners. The UNM Cancer Center has very active Hispanic/Latino and Native American outreach programs that provide education and services to New Mexico's minority populations.
Serving a vast geographic region of great beauty, with rich multicultural and multiethnic diversity, tremendous scientific opportunity, and challenging health and socioeconomic disparities, the NM MBCCOP is committed to making significant advances in cancer research and assuring access and participation in NCI-sponsored clinical trials to our regional communities. The special populations served by the NM MBCCOP - primarily Hispanic/Latino, American Indian, and non- Hispanic White - have strikingly different patterns of cancer incidence, mortality, and cancer health disparities. The continuation of funding for this grant will allow the NM MBCCOP to continue to offer cancer clinical trials to the diverse cultures we serve.
|Othus, Megan; Appelbaum, Frederick R; Petersdorf, Stephen H et al. (2015) Fate of patients with newly diagnosed acute myeloid leukemia who fail primary induction therapy. Biol Blood Marrow Transplant 21:559-64|
|Budd, George T; Barlow, William E; Moore, Halle C F et al. (2015) SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. J Clin Oncol 33:58-64|
|Ou, Sai-Hong Ignatius; Moon, James; Garland, Linda L et al. (2015) SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM). J Thorac Oncol 10:387-91|
|Coutre, Steven E; Othus, Megan; Powell, Bayard et al. (2014) Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Br J Haematol 165:497-503|
|Kernstine, Kemp H; Moon, James; Kraut, Michael J et al. (2014) Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220. Ann Thorac Surg 98:402-10|
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Flaherty, Lawrence E; Othus, Megan; Atkins, Michael B et al. (2014) Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group B, Ch J Clin Oncol 32:3771-8|
|Advani, Anjali S; McDonough, Shannon; Copelan, Edward et al. (2014) SWOG0919: a Phase 2 study of idarubicin and cytarabine in combination with pravastatin for relapsed acute myeloid leukaemia. Br J Haematol 167:233-7|
|Philip, Philip A; Goldman, Bryan; Ramanathan, Ramesh K et al. (2014) Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWO Cancer 120:2980-5|
|Smerage, Jeffrey B; Barlow, William E; Hortobagyi, Gabriel N et al. (2014) Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. J Clin Oncol 32:3483-9|
Showing the most recent 10 out of 49 publications